- Home
- CHCT vs MNMD Comparison
CHCT vs MNMD Comparison
Compare CHCT & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- MNMD
- Stock Information
- Founded
- CHCT 2014
- MNMD 2019
- Country
- CHCT United States
- MNMD United States
- Employees
- CHCT N/A
- MNMD N/A
- Industry
- CHCT Real Estate Investment Trusts
- MNMD Pharmaceuticals and Biotechnology
- Sector
- CHCT Real Estate
- MNMD Health Care
- Exchange
- CHCT Nasdaq
- MNMD Nasdaq
- Market Cap
- CHCT 479.2M
- MNMD 541.7M
- IPO Year
- CHCT 2015
- MNMD N/A
- Fundamental
- Price
- CHCT $17.30
- MNMD $7.08
- Analyst Decision
- CHCT Buy
- MNMD Strong Buy
- Analyst Count
- CHCT 4
- MNMD 8
- Target Price
- CHCT $21.00
- MNMD $26.29
- AVG Volume (30 Days)
- CHCT 268.5K
- MNMD 1.2M
- Earning Date
- CHCT 07-29-2025
- MNMD 08-12-2025
- Dividend Yield
- CHCT 10.90%
- MNMD N/A
- EPS Growth
- CHCT N/A
- MNMD N/A
- EPS
- CHCT N/A
- MNMD N/A
- Revenue
- CHCT $116,531,000.00
- MNMD N/A
- Revenue This Year
- CHCT $7.71
- MNMD N/A
- Revenue Next Year
- CHCT $7.53
- MNMD N/A
- P/E Ratio
- CHCT N/A
- MNMD N/A
- Revenue Growth
- CHCT 1.33
- MNMD N/A
- 52 Week Low
- CHCT $14.76
- MNMD $4.70
- 52 Week High
- CHCT $27.62
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- CHCT 60.30
- MNMD 51.96
- Support Level
- CHCT $16.44
- MNMD $6.40
- Resistance Level
- CHCT $17.18
- MNMD $7.29
- Average True Range (ATR)
- CHCT 0.41
- MNMD 0.44
- MACD
- CHCT 0.04
- MNMD -0.06
- Stochastic Oscillator
- CHCT 83.77
- MNMD 64.08
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).